<DOC>
	<DOCNO>NCT00249860</DOCNO>
	<brief_summary>The main objective study establish interferon-beta-1a treatment choice chronic Hepatitis C well efficacy safety profile monotherapy combination therapy . This multicenter , randomize , double-blind , placebo-controlled study placebo crossed-over combination interferon-beta-1a ribavirin treatment open-label extension phase . The duration trial 48 week , double-blind period 12 week . The study recruit 257 eligible subject either sex . It conduct approximately 16 Investigators / investigational center 3 country ( China , Hong Kong Singapore ) .</brief_summary>
	<brief_title>A Multicenter Phase 3 Study Interferon-beta-1a Treatment Chronic Hepatitis C Asian Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Age 18 65 year Have elevate serum alanine aminotransferase ( ALT ) 1.5 10 time upper limit normal Had adequate bone marrow reserve organ function Are pregnant willing use contraception , , childbearing potential Are willing able comply protocol give write informed consent Other protocol define inclusion criterion may apply Clinical evidence liver cirrhosis diagnosis definite cirrhosis liver biopsy History liver failure , severe retinopathy , immunologically mediated disease , cancer epilepsy history inadequately control seizure Any cause liver disease chronic hepatitis C Evidence chronic renal impairment , liver cancer , unstable psychiatric disorder , know ongoing alcohol drug abuse Positive test screen Hepatitis B surface antigen , immunoglobulin M Hepatitis B core antibody human immunodeficiency virus antibody Previous systemic treatment Hepatitis C interferon ribavirin Presence systemic disease might interfere subject safety , compliance evaluation Known allergy acetaminophen , human serum albumin mannitol ; Glucocorticosteroids immunosuppressive drug take within 28 day start treatment Bearing organ transplant ( except cornea ) Other protocol define exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Subjects chronic hepatitis C never previously receive interferon therapy .</keyword>
</DOC>